Comparative Pharmacology
Head-to-head clinical analysis: DURAGESIC 37 versus JOBEVNE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURAGESIC 37 versus JOBEVNE.
DURAGESIC-37 vs JOBEVNE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl binds to mu-opioid receptors, activating G-protein coupled receptor signaling, leading to inhibition of adenylate cyclase, decreased cAMP production, and modulation of ion channels (increased potassium efflux, decreased calcium influx). This results in reduced neuronal excitability, inhibition of nociceptive transmission, and altered pain perception. Additionally, fentanyl may interact with other opioid receptors (kappa, delta) with lower affinity.
JOBEVNE is a monoclonal antibody that binds to and inhibits the activity of a specific cytokine receptor, reducing inflammatory signaling.
Initial: 25 mcg/hour transdermal patch applied every 72 hours. Titrate based on opioid tolerance. For opioid-naive patients: 12 mcg/hour patch.
100 mg intravenously every 12 hours.
None Documented
None Documented
Terminal elimination half-life 20-27 hours (range 13-42 h) after transdermal removal; due to continuous absorption from skin depot, effective half-life is longer during patch wear.
Terminal half-life: 12-15 hours; clinical context: supports twice-daily dosing in most patients
Primarily renal: 75% as metabolites (mostly norfentanyl) and <10% unchanged drug. Fecal: 9% via biliary elimination.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Category C
Category C
Opioid Analgesic
Opioid Analgesic